A clinical decision support tool that monitors changes in blood-based tumor mutational burden (bTMB)—the number of mutations in the tumor's DNA found in the blood—to identify early signs of drug resistance. It helps oncologists detect molecular progression via liquid biopsies before it becomes visible on medical imaging.
The PESTEL analysis reveals a high-potential innovation strongly supported by technological advancements in NGS and a social shift toward precision medicine, but one that faces significant hurdles in reimbursement and strict regulatory validation. The tool's success depends on transitioning from a research-grade observation to a clinically validated standard of care that justifies the cost of frequent serial sampling.
Political2
Economic3
Social2
Technological3
Environmental2
Legal3
The tool's viability depends heavily on healthcare regulations, FDA approval for clinical decision support, and the technological adoption of liquid biopsy standards. · Generated 2026-10-08 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated